Serial killers and mass murderers: Engineered T cells Are up to the task

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 470-472

  June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE CELL THERAPY; ADOPTIVE TRANSFER; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ENGINEERING; CELL SURFACE; CELL THERAPY; HUMAN; LYMPHOCYTE DIFFERENTIATION; NATURAL KILLER CELL; NONHUMAN; NOTE; PROTEIN EXPRESSION; SYSTEMS BIOLOGY; T LYMPHOCYTE; TIME-LAPSE VIDEO MICROSCOPY; TUMOR MICROENVIRONMENT; ANIMAL; CD8+ T LYMPHOCYTE; IMMUNOLOGY; NEOPLASM;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN;

EID: 84957410353     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0075     Document Type: Note

References (34)

1. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015;7:280ps7.
2. Kalos M, June CH. Adoptive T-cell transfer forcancer immunotherapy in the era of synthetic biology. Immunity 2013;39:49-60.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33.
4. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
5. Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N, et al. Sustained remissions with chimeric antigen receptor T cells for leukemia. N Engl J Med 2014;371:1507-17.
6. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
7. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
8. + T cells in a patient with epithelial cancer. Science 2014;344:641-5.
9. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014;257:56-71.
10. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52.
11. Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res 2015;3:483-94.
12. + T cells can participate in efficient multikilling through conjugation to multiple tumor cells. Cancer Immunol Res 2015;3:473-82.
13. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 1995;25:1071-9.
14. Zagury D, Bernard J, Thierness N, Feldman M, Berke G. Isolation and characterization of individual functionally reactive cytotoxic T lymphocytes: conjugation, killing and recycling at the single cell level. Eur J Immunol 1975;5:818-22.
15. Choi PJ, Mitchison TJ. Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells. Proc Natl Acad Sci U S A 2013;110:6488-93.
16. Deguine J, Breart B, Lemaitre F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity 2010;33:632-44.
17. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, et al. Control of HIV-1 immune escape by CD8 Tcells expressing enhanced T-cell receptor. Nat Med 2008;14:1390-5.
18. Tan MP, Gerry AB, Brewer JE, Melchiori L, Bridgeman JS, Bennett AD, et al. TCR binding affinity governs the functional profileofcancer-specific CD8 T cells. Clin Exp Immunol 2014 Dec 15. [Epub ahead of print].
19. Hombach A, Heuser C, Gerken M, Fischer B, Lewalter K, Diehl V, et al. T cell activation by recombinant Fcepsilon RI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther 2000; 7: 1067-75.
20. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015;3:125-35.
21. Frigault MJ, Lee J, Basil M, Carpenito C, Motohashi S, Scholler J, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015;3:356-67.
22. Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J 2014;20:141-4.
23. + T cells. Cancer Res 2007;67: 11428-37.
24. Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MWL, Street SE, et al. Adoptive transfer of gene-engineered CD4(+) helper T cells induces potent primary and secondary tumor rejection. Blood 2005; 106:2995-3003.
25. Brentjens R, Riviere I, Park J, Davila M, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
26. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 2014;124:1070-80.
27. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494: 361-5.
28. Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology 2013;2:e26677.
29. Singh H, Moyes JS, Huls MH, Cooper LJ. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther 2015;22:95-100.
30. Mestas J, Hughes CC. Ofmice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8.
31. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-12.
32. Lopez JA, Jenkins MR, Rudd-Schmidt JA, Brennan AJ, Danne JC, Mannering SI, et al. Rapid and unidirectional perforin pore delivery at the cytotoxic immune synapse. J Immunol 2013;191:2328-34.
33. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115:98-104.
34. + T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One 2014;9: e87873.